In this article:

Immunic (IMUX) Receives a Buy from JMP Securities

In this article:
In this article:

JMP Securities analyst Gobind Singh reiterated a Buy rating on Immunic (IMUXResearch Report) yesterday and set a price target of $58.00. The company’s shares closed last Tuesday at $11.32.

According to, Singh has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -21.4% and a 33.3% success rate. Singh covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Kaleido Biosciences, and Seres Therapeutics.

Immunic has an analyst consensus of Strong Buy, with a price target consensus of $48.00.

See Insiders’ Hot Stocks on TipRanks >>

Immunic’s market cap is currently $311.1M and has a P/E ratio of -3.16.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Immunic, Inc. engages in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.

Read More on IMUX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More